Active — Not RecruitingNot Applicable

Prediction of LVAR and MACE in AMI Though Plasma Multiomics Analysis

China1,000 participantsStarted 2025-01-01

Plain-language summary

To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years.
✓. Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).
✓. Willingness to provide informed consent.

Exclusion criteria

✕. Prior surgery or trauma.
✕. Renal failure with glomerular filtration \<30 ml/min.

What they're measuring

major adverse cardiovascular events

Timeframe: 2025-1-1 to 2027-12-31

Trial details

NCT IDNCT06885619

SponsorBeijing Anzhen Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

View on ClinicalTrials.gov More Acute Myocardial Infarction (AMI) trials